View Clinical Trial (Medical Research Study)

A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 - NCT00934089-90025(Clinical Trial 301016)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Los Angeles
State:  
CA
Zip Code: 90025
Conditions: Glaucoma, Open-Angle - Ocular Hypertension
Purpose: This study will characterize the effect of PF-04217329, alone and in combination with latanoprost, on circadian intraocular pressure and blood pressure in glaucoma patients. Blood samples will be collected to measure the amount of active metabolite of PF-04217329 in the plasma following dosing.
Study summary:
Criteria: Inclusion Criteria: - Diagnosis of primary open-angle glaucoma or ocular hypertension in one or both eyes - IOP of at least 22 mmHg and not more than 30 mmHg in either eye at 8 AM after discontinuing previous glaucoma treatment - Visual acuity correctable to 20/100 or better in each eye. Exclusion Criteria: - Closed/barely open anterior chamber angle or a history of acute angle closure in either eye. - Diagnosis of a clinically significant or progressive retinal disease (eg, diabetic retinopathy, macular degeneration) in either eye. - Advanced glaucoma or a history of severe central visual field loss in either eye. - History of ocular surgery or trauma in either eye within 6 months of the screening visit. - History of ocular infection, ocular inflammation, or laser surgery in either eye within 3 months of the screening visit.
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: October 7, 2010
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.